Back

Cui bono? “This week we learned that review panels for major #Alzheimer’s clinical trials that were meeting in late Jan. have been cancelled,” Suzanne Schindler, a neurologist at the Washington U School of Medicine . . . “Progress in clinical trial diversity is not just a regulatory box to check; it’s a moral imperative & a scientific necessity,” Neil Weisman, pres. of Continuum Clinical, a co. that helps recruit participants for clinical trials, inc. early AD."

https://www.beingpatient.com/nih-grinds-to-halt-under-trump-comms-ban/